PartnershipJul 22, 2026, 04:08 PM
Tempest Partners Senlang for TPST-4003 CAR-T Development in China
AI Summary
Tempest Therapeutics entered a collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop its TPST-4003 in vivo CAR-T product candidate. The partnership will initiate an investigator-initiated trial (IIT) in China for approximately 10 patients with myasthenia gravis or multiple sclerosis, with first patient dosing expected in Q4 2026. Tempest will pay Senlang development fees ranging from $1.5 million to $2.0 million per product, and Senlang gains an exclusive option for China rights.
Key Highlights
- Tempest Therapeutics partnered with Heibei Senlang Biotechnology for TPST-4003 development.
- Collaboration focuses on TPST-4003, a CD7-targeted in vivo CAR-T candidate.
- An investigator-initiated trial (IIT) will evaluate TPST-4003 in China.
- The IIT will involve approximately 10 patients with myasthenia gravis or multiple sclerosis.
- First patient enrollment and dosing are expected in Q4 2026.
- Tempest will pay Senlang $1.5 million to $2.0 million in development fees per product.
- Senlang receives an exclusive option for China rights to TPST-4003.
Price Impact
More from TPST